secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001404644-24-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports FY2023 net loss $36.3M; Rett gene therapy trial expanded, cash runway to H2 2026
--------------------------------------------------------------------------------

- Cash and investments $197.2M at Dec 31, 2023; reverse merger and $95M private placement completed December 2023.
- FY2023 net loss $36.3M vs $55.2M prior year; Q4 net income $2.4M from $16.4M bargain purchase gain.
- R&D expenses $44.4M (down from $47.5M), G&A $11.2M (up from $9.0M) due to reverse merger costs.
- Phase 1/2 NGN-401 Rett syndrome trial expanded with high-dose Cohort 2; interim clinical data expected 4Q24.
- Appointed Dr. Julie Jordan as CMO; CLN5 Batten disease trial interim data and regulatory update expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/0001404644-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/ngne-20240318.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer